WVP
RCUS icon

Worth Venture Partners’s Arcus Biosciences RCUS Stock Holding History

Worth Venture Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-67,300
Closed -$133K – 186
2023
Q2 		$133K Buy
67,300
+41,500
+161% +$790K 0.07% 126
2023
Q1 		$61.1K Buy
+25,800
New +$493K 0.03% 151

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Worth Venture Partners's RCUS Position: Q2 2023 in Review

Worth Venture Partners sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 12,700 shares — an estimated $242K sold.

Worth Venture Partners first reported a position in RCUS in Q1 2022 and held it in 2 quarters. The position peaked at $249K in Q1 2022. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

  • Worth Venture Partners reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
  • Worth Venture Partners sold 12,700 Arcus Biosciences shares in Q2 2023, an estimated $242K.
  • Worth Venture Partners first reported a position in Arcus Biosciences in Q1 2022 and held it in 2 quarters.
  • Worth Venture Partners's Arcus Biosciences position peaked at $249K in Q1 2022.
  • 181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.